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Abstract
Macular degeneration is the leading cause of vision loss in Americans sixty years and older. Currently, it is an incurable
disease. Stem cell therapy is the idea of transplanting stem cells to replace damaged cells in the body. As the demand
for transplantable organs far outweighs the supply, stem cells are an encouraging alternative to replace damaged cells.
Can stem cell therapy be the first cure for macular degeneration? Many experiments have been done on transplanting
stem cells into the eyes of rats with macular degeneration yielding promising results. The first transplantation of retinal
pigmented epithelial stem cells into humans to treat macular degeneration was done in 2012. Stem cells were differentiated and inserted into two patients suffering from macular degeneration. Both patients that partook in the study
displayed significant visual improvement, and no abnormal growth was observed. In another study, the use of retinal
epithelial cells vs. the use of other types of eye cells to treat macular degeneration was studied. Each cell type has the
same potential for use in stem cell therapy. Stem cell therapy is a hopeful option for treatment of macular degeneration.
Further research is needed before it can be used as a widespread cure.
Introduction
Two important characteristics distinguish stem cells from other
cells. Firstly, they are unspecialized cells that have the ability to
renew themselves through cell division, and secondly under
certain conditions they can be induced to become tissue or
organ-specific cells with special functions.
Until recently, scientists have mainly worked with embryonic
stem cells and somatic stem cells. Embryonic stem cells are
from the blastocyst of the embryo. The blastocyst is composed
of an inner cell mass of stem cells that differentiate into different types of cells, giving rise to the entire body of the organism.
Embryonic stem cells are donated for research purposes by
eggs that have been fertilized in vitro, and they are not derived
from eggs fertilized in a women’s body. The donated stem cells
are transferred to a culture dish that contains a nutrient broth
called a culture medium where they divide and spread over the
surface of the culture dish. When stem cells are grown under
specific conditions, they can remain unspecialized. If the stem cells
are allowed to clump together to form embryoid bodies, spontaneously they will begin to differentiate. Scientists can modify the
stem cells by inserting specific genes or by changing the chemical
make-up of the culture. Figure 1 illustrates the process of modifying stem cells to become gene specific stem cells.
Figure 1: Stem cells
clump together to
form embryoid bodies,
and spontaneously
they will begin to
differentiate.The stem
cells can be modified
by inserting specific
genes. (Bethesda,
2016)

Adult stem cells are different from embryonic stem cells because they are found in mature tissues or organs. Adult stem
cells are undifferentiated cells that can develop into specific
cells of the tissue or organ where it is found. Adult stem cells
are found in a specialized region called the stem cell niche.
When needed the stem cells will divide and differentiate. This
can occur when there is tissue damage or under normal wear
and tear conditions – the stem cells will divide in order to replenish the supply of cells.There are various types of adult stem
cells that can differentiate into numerous types of cells hematopoietic stem cells (develop into blood cells), mesenchymal stem
cells (develop into bone cells, cartilage cells and fat cells), and
neural stem cells (develop into cells of the nervous system).
Human induced pluripotent stem cells are an additional type of
stem cell. This stem cell is an adult cell that has been genetically
reprogrammed to express the characteristics of an embryonic
stem cell. The method used to reprogram these cells help researchers learn more about the possibility of reprogramming
damaged or diseased cells in the human body.
Human stem cells have many uses in research and clinic. The
most important use being cell-based therapy. Cell-based therapy
is the potential to direct the differentiation of stem cells in order
to transplant them as replacement cells or tissue. Today, tissue
and organs are being donated, but the need for transplantable
organs and tissue far outweighs the supply. Cell-based therapy
can offer a renewable source of replacement cells which can be
used to treat different diseases. (Bethesda, 2016).
There are several drawbacks of using transplanted stem cells to treat
disease including rejection and long-term side effects are not known.
Therefore, a lot of research is still being done before stem cell therapy is used as an established treatment for disease. (Ladock, 2016).
One disease scientists believe stem cell therapy can treat is macular degeneration. Macular degeneration is the most common
cause of vision loss affecting more than 10 million Americans.
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The retina is the part of the eye that records the images we see
and sends them via the optic nerve to the brain. The macula is
located in the central area of the retina and is responsible for
focusing central vision, seeing fine details, and recognizing faces
Figure 2: Anatomy of the human eye showing the location
of the macula. (ISSCR, 2015)

retina that is responsible for central vision. Researchers have
been studying the possibility of using stem cells to treat macular degeneration. The macula is made up of photoreceptor
cells called rods and cones. Rods and cones respond to light by
sending electrical impulses to the brain through the optic nerve.
The brain then interprets these impulses. Behind the rods and
cones is a layer of cells called retinal pigmented epithelial cells.
(ISSCR, 2015).

Functions of Retinal Pigmented Epithelium

and color. The anatomy of the human eye is illustrated in figure
2 with the location of the macula shown. Macular degeneration
is a disease which causes the deterioration of the cells of the
macula. At the present time it is an incurable disease.
Age-related macular degeneration is the most common cause of
blindness in people over the age of 60 years old.Age-related macular degeneration gets progressively worse as one ages. It starts
with the dysfunction and death of retinal pigment epithelial (RPE)
cells. It continues with photoreceptor loss, and insufficiencies
in high acuity vision. There are 3 stages of age-related macular
degeneration. Early age-related macular degeneration is the first
stage where vision loss is not experienced. It can be diagnosed by
the presence of small yellow droplets beneath the retina called
drusen. The second stage is called intermediate age-related macular degeneration where some vision loss may be experienced. A
comprehensive eye exam will look for drusen or pigment change
in the retina. The last stage is called late age-related macular degeneration.At this stage vision loss is noticeable. (Buchholz, 2009)
It is known that the causes of macular degeneration are both
genetic and environmental, but the exact cause is not known.
Age is the biggest risk; there is more of a chance one will develop macular degeneration as one ages. (Akpek, 2013).

Methods
Literature for this article was obtained primarily using Touro
College Online library. Other databases such as PubMed were
used. Additionally, Google Scholar was valuable for finding necessary and relevant articles.

Discussion
Only 5.5 millimeters in diameter, the macula is a part of the
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Retinal pigmented epithelial cells have many functions in the
eye. Firstly, these cells are responsible for transport in two
directions. In one direction they transport glucose and other
nutrients from the blood to the rods and cones. In the other
direction the transport electrolytes and water from the subretinal area to the choroid. Another function of retinal pigmented
epithelial cells is to absorb and filter entering light. The retina
is made up of various pigments that are sensitive to different
wavelengths of light. Additionally, retinal pigmented epithelial
cells are responsible for phagocytosis. (Simó Et. Al. 2010)
The eye is an excellent part of the body for researchers to test
stem cell therapy on because the eye is well contained by its
many barriers. It is hard for the stem cells to move to other
parts of the body. Additionally, researchers can assess the differences between a treated and untreated eye on the same patient.
There is equipment available that allows one to see the interior
and exterior of a person’s eye.
The focus of scientists has been on using retinal pigmented
epithelial cells for stem cell therapy. This is because it is a lot
harder to ensure the proper placement of rods and cones in a
patient’s eye. Rods and cones connect with nerve fibers, and it is
extremely complex to correctly integrate these photoreceptor
cells with the nerve fibers. Retinal pigmented epithelial cells do
not connect to nerve fibers; therefore they are a better option
for stem cell therapy.
It is the goal of scientists to be able to transplant retinal pigmented epithelial cells before the disease has progressed such that
the photoreceptor cells have died. In this way, the transplanted
retinal pigmented epithelial cells can take on some function of
the damaged retinal pigmented epithelial cells and prevent the
rod and cone cells from dying, thereby stopping the progression
of the disease. (ISSCR, 2015).

Delivery of Stem Cells into the Eye
The following method was used to deliver retinal epithelial
cells into rats. The rat was put under anesthesia. A sharp sterilized needle was inserted to make a hole right beneath the
limbus, which is the border between the cornea and the sclera
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of the eye. The tip of the syringe was inserted into the hole,
injecting the retinal pigmented epithelial cells. The syringe was
then taken out slowly, and eye moisturizing drops were given.
(Westenskow Et. Al. 2015).
A study of rats with macular degeneration, treated with human
embryonic stem cells has shown evidence of rescued photoreceptors and vision loss prevention. Three different levels of
pigmented cells were used; light, medium and heavy. Different
amount of cells were used in each group of rats. Visual acuity
improved in the groups of rats treated with a dose of between
5,000 – 100,000 retinal pigmented epithelial cells. The cells injected into the rats sustained visual function for at least 60 days.
The cells survived in the rats for at least 220 days. All the groups
of rats showed deterioration of visual acuity over time. There
is no evidence that showed any group having a slower deterioration over time. The deterioration of the visual acuity of the
rats in this study may be related to the inadequate use of immunosuppressive drugs to treat the rats. Another hypothesis of
why the cells didn’t last is that cell transplantation may need to
be repeated several times in order to sustain their therapeutic
effect. The study confirmed the long-term safety of retinal pigmented epithelial cells for treatment of macular degeneration
in rats. It is a promising step in the research of stem cell therapy
to treat specific types of macular degeneration in humans. (Lu
Et. Al. 2009).
In one study researchers tested whether human embryonic
stem cells can safely be used to treat patients with macular
degeneration. Although human embryonic stem cells were first
discovered in 1998, this was the first study to report transplanting human embryonic stem cells into human patients. The
study tested for signs of hyperproliferation, carcinogenicity,
abnormal tissue formation, and rejection. Two patients were
selected for the study. One patient had dry age-related macular
degeneration and the other had Stargardt’s macular dystrophy
(most common pediatric macular degeneration). (Schwartz Et.
Al. 2012).
In the experiment human embryonic stem cell culture MA09
(classification of human embryonic stem cells) were used to
generate a master cell bank. (Schwartz Et. Al. 2012) Cell line
MA09 has contact with the environment before transplanted
into the patient and therefore is classified as a xenotransplantation. Xenotransplantation is any procedure that involves the
transplantation, infusion, or implantation to humans of nonhuman live cells. (Samdani, 2014) After embryoid bodies were
formed and there was multiplication of the cells, retinal pigment
epithelial patches were isolated. Embryoid bodies are the first
phase of embryonic stem cell differentiation. There are various
ways to form embryoid bodies, but it has been a challenge to

form embryoid bodies uniform in size. (Xu Et. Al. 2011) The
retinal pigmented epithelial cells were tested for pathogens and
phagocytosis. They were also tested for RPE and hESC markers.
Human embryonic retinal pigment cells were successfully cultured. The cells showed typical retinal pigmented epithelial cell
behavior by losing their pigmented cobblestone morphology
during proliferation and re-differentiating into a monolayer of
polygonal cuboidal pigmented epithelium.
One hundred and fifty nanoliters of retinal pigmented epithelial
cells were injected into the patients’ eyes through a cannula that
delivered a dose of 500,000 viable retinal pigmented epithelial
cells into the subretinal space. Immunosuppressive drugs; tacrolimus and mycophenolate mofetil were given to each patient a
week before the surgery and continued for six weeks after the
surgery. Tacrolimus was not given after week six and the mycophenolate mofetil was continued for an additional six weeks.
(Schwartz Et. Al. 2012).
There was no hyperproliferation or abnormal growth in either
of the patients following surgery as determined by biomicroscopic and ophthalmoscopic clinical examinations. (Schwartz Et.
Al. 2012).
Anatomical evidence showed survival of human embryonic
stem cells in the patient with Stargardt’s macular dystrophy.The
transplanted cells were localized to exactly the correct anatomical location. Increased pigmentation was seen in the retinal
pigmented epithelial cells beginning from week one after the
surgery up until month three after the surgery.
The patient with age-related macular degeneration did not take
the immunosuppressive drugs after the operation; therefore
anatomical evidence was difficult to confirm.
Both patients displayed functional visual improvement. The
Figure 3: A
series of images
showing the
macula before
the operation
until after the
operation.
Increased RPE
are seen post
operation.
(Schwartz Et.
Al. 2012)
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patient with Stargardt’s macular dystrophy was able to read study
letters of 20/500 immediately following surgery. By week six, the
patient was reading letters of 20/320 which remained stable
through the postoperative period. The patient with age-related
macular degeneration showed mild visual improvements.
The series of images in figure 4 illustrate the area in the eye called
the macula from before the operation until after the operation.
Increased retinal pigmented epithelial cells are seen post operation.
In this study human embryonic stem cells were safely transplanted into 2 patients. (Schwartz Et. Al. 2012).
A second study compared the effectiveness of using human induced pluripotent cells with using human embryonic stem cells.
Both types of stem cells have the ability to differentiate, but it is
unclear if they both have the same potential for use in stem cell
therapy. The results were determined by finding differentiating
ocular cells called retinal pigmented epithelium (RPE).
Transcription factors, protein arrangement, and gene expression
were looked at when comparing the two types of stem cells.
The study concluded that human induced pluripotent stem
cells are a feasible candidate for cellular therapy since they have
similar cellular function and possess proper gene expression.
(Buchholz Et. Al. 2009).

Where we are now

must be performed.
Scar tissue is present in the damaged eyes of patients with macular degeneration. When new cells are transplanted there is a
barrier between the host retina and the grafted cells. This can
affect the way the light is transmitted, and the way the patients
will see. Treating patients before scar tissue has formed, or discovering ways to get rid of scar tissue is crucial before stem
cells can be transplanted. (Barnstable).

Conclusion
There is promising research for use of retinal pigmented epithelial cells to treat macular degeneration. Continued research
is needed before stem cell therapy can be used as a widespread
treatment for macular degeneration. It is a goal of researchers
to treat patients earlier on in the progression of the disease,
before complete visual function has been lost.
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